Kelly Cox
Adult Health · Jacksonville Beach, FLNPI 1275937179
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Biohaven Pharmaceutical Holding Company Ltd. at 54.0% of the total. Reporting peaked in 2022 at $10,664 and has fallen 73.0% since, to $2,880 in 2025. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 488 payments — averaging $38.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$10K
- AbbVie$1K
- Eisai Inc.$947
- Lilly USA, LLC$666
- Biogen$649
- Novartis$539
- plus $4K from 33 others
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$9,49550%
- Travel & lodging$3042%
- Food & beverage$8,77947%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$9,911
- TYSABRI$300
- UPLIZNA$122
How this compares
$18,878 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 16 | $154,373 |
| RexultiBrexpiprazole | 33 | $48,054 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $14,705 |
| XcopriCenobamate | 12 | $14,264 |
| Dalfampridine ErDalfampridine | 11 | $6,600 |
| RivastigmineRivastigmine Tartrate | 122 | $6,539 |
| BelsomraSuvorexant | 12 | $5,367 |
| Rivastigmine | 17 | $3,369 |
| Memantine Hcl | 108 | $2,324 |
| Rosuvastatin Calcium | 136 | $1,818 |
| Donepezil Hcl | 141 | $1,367 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $617 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $486 |
| Buspirone Hcl | 31 | $448 |
| Hydroxyzine Hcl | 12 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $332 | $48,05433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Jacksonville Beach
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Cynthia OteroMaitland$31K
- Jennifer GodshallTampa$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.